Fuwai Hospital, National Key Laboratory, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.
J Cardiovasc Electrophysiol. 2024 May;35(5):1007-1016. doi: 10.1111/jce.16238. Epub 2024 Mar 11.
Cather ablation (CA) is a well-recognized treatment alternative for atrial fibrillation (AF) patients despite more than 20% ablation-treated patients suffering from AF recurrence. The underlying mechanism of AF recurrence postablation is probably associated with high cardiac parasympathetic activity, which can be assessed with deceleration capacity (DC) of heart rate. Given that the relationship between DC and AF recurrence is still controversial, this systematic review and meta-analysis was performed to investigate the characteristics of DC in patients with and without AF recurrence, evaluating the prognostic value of DC in AF patients after CA.
A literature search was systematically performed in the Embase, PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases until October 01, 2023. The observational studies reporting either the pre- and postablation DC in both recurrence and non-recurrence groups or the ratios based on DC for predicting AF recurrence were mainly included. Weighted mean differences (WMD) or odds ratios (OR) based on DC would be calculated with a random-effect model, if heterogeneity estimated with the I index and Q statistic was significant (I > 50% or p < .05); otherwise, a fixed-effect model would be utilized.
A total of eight observational studies involving 914 AF patients treated with radiofrequency or cryoballoon ablation were included in this study. Ablation-treated patients with AF recurrence had the higher DC postablation in relation to those without recurrence (WMD, 1.00; 95% confidence interval [CI], 0.33-1.67; p < .01), which was present up to 3 months of follow-up (WMD, 1.54; 95% CI, 1.11-1.96; p < .01), whereas there was no statistical significance in DC before ablation between recurrence and non-recurrence groups (WMD, 0.34; 95% CI, -0.12 to 0.79; p = .15). The high DC postablation was a risk factor for AF recurrence in ablation-treated patients (OR, 2.17; 95% CI, 1.44-3.25; p < .01).
The high DC postablation was associated with the risk of AF recurrence, suggesting that DC may act as a prognostic indicator in AF patients treated with CA.
尽管有超过 20%的消融治疗患者出现房颤复发,但导管消融(CA)仍是治疗房颤的一种公认的替代方法。消融后房颤复发的潜在机制可能与心脏高副交感神经活动有关,这可以通过心率减速能力(DC)来评估。鉴于 DC 与房颤复发之间的关系仍存在争议,因此进行了这项系统评价和荟萃分析,以研究消融后有和无房颤复发患者的 DC 特征,评估 CA 后 DC 对房颤患者的预后价值。
系统检索了 Embase、PubMed、Web of Science、中国知网(CNKI)和万方数据库,检索时间截至 2023 年 10 月 01 日。主要纳入了报告消融后复发组和未复发组的术前和术后 DC 或基于 DC 的比值以预测房颤复发的观察性研究。如果使用 I 指数和 Q 统计量估计的异质性显著(I>50%或 p<0.05),则使用随机效应模型计算基于 DC 的加权均数差(WMD)或比值比(OR);否则,使用固定效应模型。
这项研究共纳入了 8 项观察性研究,共 914 例接受射频或冷冻球囊消融治疗的房颤患者。与无复发患者相比,消融后有房颤复发的患者的 DC 更高(WMD,1.00;95%置信区间[CI],0.33-1.67;p<0.01),这种情况一直持续到 3 个月的随访期(WMD,1.54;95%CI,1.11-1.96;p<0.01),而复发组和未复发组之间消融前的 DC 没有统计学意义(WMD,0.34;95%CI,-0.12 至 0.79;p=0.15)。消融后 DC 较高是消融治疗患者房颤复发的危险因素(OR,2.17;95%CI,1.44-3.25;p<0.01)。
消融后 DC 较高与房颤复发的风险相关,这表明 DC 可能是 CA 治疗的房颤患者的预后指标。